# reload+after+2024-01-20 01:43:36.071537
address1§3160 Porter Drive
address2§Suite 250
city§Palo Alto
state§CA
zip§94304
country§United States
phone§650 391 9740
website§https://www.bridgebio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
fullTimeEmployees§392
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Neil  Kumar Ph.D.', 'age': 44, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 2102918, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Charles J. Homcy M.D.', 'age': 75, 'title': 'Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director', 'yearBorn': 1948, 'fiscalYear': 2022, 'totalPay': 208000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Brian C. Stephenson C.F.A., Ph.D.', 'age': 42, 'title': 'CFO & Secretary', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 1149700, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard H. Scheller Ph.D.', 'age': 70, 'title': 'Chairman of Research & Development', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 202400, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Frank P. McCormick Ph.D.', 'age': 73, 'title': 'Co-Founder, Chairman of Oncology & Director', 'yearBorn': 1950, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Uma  Sinha Ph.D.', 'age': 66, 'title': 'Chief Scientific Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 1313457, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Grace  Rauh', 'title': 'Vice President of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eli M. Wallace Ph.D.', 'age': 56, 'title': 'Chief Scientific Officer of Oncology', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thomas  Trimarchi Ph.D.', 'title': 'Chief Product Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eric Michael David J.D., M.D., Ph.D.', 'age': 51, 'title': 'Chief Executive Officer of Gene Therapy', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§10
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.074
priceToSalesTrailing12Months§695.4621
currency§USD
dateShortInterest§1702598400
forwardEps§-3.54
pegRatio§0.17
exchange§NMS
quoteType§EQUITY
shortName§BridgeBio Pharma, Inc.
longName§BridgeBio Pharma, Inc.
firstTradeDateEpochUtc§1561642200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d3adccf0-6693-305c-9651-8da79033d61c
gmtOffSetMilliseconds§-18000000
targetHighPrice§60.0
targetLowPrice§28.0
targetMeanPrice§47.27
targetMedianPrice§50.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§5.171
grossMargins§0.73536
ebitdaMargins§0.0
trailingPegRatio§None
